A test that measures tumor DNA in the blood could be a helpful prognostic factor in patients with colorectal cancer who ...
Patients with HER2-low gastric cancer tended to have distinct characteristics compared to those with HER2-negative or ...
A multi-institutional team led by scientists from the Medical College of Wisconsin (MCW) Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen ...
Testing for molecular residual disease was able to identify patients with early-stage colorectal cancer who are most likely ...
Using data from the UK Biobank, potential correlations were investigated between excessive skin scarring outcomes arising ...
A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive ...
Can high levels of hCG imply you have twins? Learn more about the “pregnancy hormone” and how weekly hCG levels can differ in ...
The data, from a large prospective cohort, support the value of chemotherapy for ctDNA-positive patients, regardless of clinical stage.
Tumor-informed circulating tumor DNA (ctDNA) testing for residual disease was able to distinguish patients with colorectal cancer (CRC) at risk for recurrence after surgery, as well as those who could ...
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor, pimicotinib ...